Masayuki Akimoto

List of Publications by Year
in descending order

10 papers	101 citations	1307594 7 h-index	1372567 10 g-index
10 all docs	10 docs citations	10 times ranked	127 citing authors

#	Article	IF	Citations
1	Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyerâ€“Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid inÂvitro. Xenobiotica, 2021, 51, 155-166.	1.1	11
2	Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Journal of Pharmaceutical Investigation, 2020, 50, 71-79.	5.3	1
3	A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes. Xenobiotica, 2020, 50, 783-792.	1.1	8
4	Comparative release studies on suppositories using the basket, paddle, dialysis tubing and flow-through cell methods I. Acetaminophen in a lipophilic base suppository. Pharmaceutical Development and Technology, 2017, 22, 130-135.	2.4	7
5	The in Vitro Release of Indomethacin from Suppositories: Effects of Bases and Comparison of Different Dissolution Methods. Chemical and Pharmaceutical Bulletin, 2017, 65, 674-677.	1.3	4
6	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 127-135.	1.6	11
7	In Vitro Characterization of the Cytochrome P450 Isoforms Involved in the Metabolism of 6-Methoxy-2-napthylacetic Acid, an Active Metabolite of the Prodrug Nabumetone. Biological and Pharmaceutical Bulletin, 2011, 34, 734-739.	1.4	17
8	Pharmacokinetic Profile of Flavin Adenine Dinucleotide, Flavin Mononucleotide and Riboflavin Following Intravenous Administration of Riboflavin or Its Coenzymes in Rats. Journal of Health Science, 2007, 53, 332-338.	0.9	2
9	Conversion of FAD to FMN and Riboflavin in Plasma: Effects of Measuring Method. Biological and Pharmaceutical Bulletin, 2006, 29, 1779-1782.	1.4	17
10	CATALYTIC ROLES OF CYP2C9 AND ITS VARIANTS (CYP2C9*2 AND CYP2C9*3) IN LORNOXICAM 5â€²-HYDROXYLATION. Drug Metabolism and Disposition, 2004, 32, 7-9.	3.3	23